Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

July 22, 2014 updated by: Myat Htut Nyunt

Molecular Assessment of Artemisinin Resistance Markers, K13 Kelch Propeller and Multi-drug Resistant Gene Polymorphism in Eastern and Western Border Areas of Myanmar

  • Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010.
  • It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar.
  • So, day-3 surveillance study have been conducted.
  • Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

91

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Myanmar
      • Yangon, Myanmar, 11191
        • Dr. Myat Phone Kyaw

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

2 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All of the malaria suspected cases were invited to participated in this study from Myanmar-Thailand border and Myanmar-Bangladesh border.

Description

Inclusion Criteria:

  • confirmed uncomplicated falciparum malaria patients.
  • age >2 years
  • box sex
  • given informed consent

Exclusion Criteria:

  • severe malaria
  • did not give informed consent
  • others diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
day-3 parasite positivity
Time Frame: 3 days
All of the enrolled patients were monitored with appropriate care up to third day and take the samples on day-3.
3 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of the drug resistance marker
Time Frame: up to day-3
By using the dried blood spots, drug resistance markers were detected by molecular method.
up to day-3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Myat Htut Nyunt

Collaborators

Kangwon National University

Investigators

  • Study Director: Myat P Kyaw, PhD, Department of Medical Research, Lower Myanmar

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2013

Primary Completion (Actual)

December 1, 2013

Study Completion (Actual)

June 1, 2014

Study Registration Dates

First Submitted

July 22, 2014

First Submitted That Met QC Criteria

July 22, 2014

First Posted (Estimate)

July 23, 2014

Study Record Updates

Last Update Posted (Estimate)

July 23, 2014

Last Update Submitted That Met QC Criteria

July 22, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WHO_3DF_2013_day3

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Day-3 Positive of Parasitaemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe